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Abstract
Noonan syndrome and related disorders are a group of clinically and genetically heteroge-
neous conditions caused by mutations in genes of the RAS/MAPK pathway. Noonan syn-
drome causes multiple congenital anomalies, which are frequently accompanied by
hypertrophic cardiomyopathy (HCM). We report here a Tunisian patient with a severe pheno-
type of Noonan syndrome including neonatal HCM, facial dysmorphism, severe failure to
thrive, cutaneous abnormalities, pectus excavatum and severe stunted growth, who died in
her eighth month of life. Using whole exome sequencing, we identified a de novo mutation
in exon 7 of the RAF1 gene: c.776C > A (p.Ser259Tyr). This mutation affects a highly
conserved serine residue, a main mediator of Raf-1 inhibition via phosphorylation. To our
knowledge the c.776C > A mutation has been previously reported in only one case with
prenatally diagnosed Noonan syndrome. Our study further supports the striking correlation
of RAF1 mutations with HCM and highlights the clinical severity of Noonan syndrome
associated with a RAF1 p.Ser259Tyr mutation.
1. Introduction
Noonan syndrome and related disorders (cardiofaciocutaneous syndrome [CFC], Costello syn-
drome [CS] and Noonan syndrome with multiple lentigines [formerly known as LEOPARD
syndrome]) are autosomal dominant disorders characterized by a wide range of symptoms
including facial dysmorphism, short stature, mental retardation and congenital heart defects
often associated with hypertrophic cardiomyopathy (HCM) (Tartaglia et al., 2011). These syn-
dromes, along with Legius syndrome and type I neurofibromatosis, are collectively known as
RASopathies and share overlapping phenotypic and molecular features, making accurate diag-
nosis challenging (Nystrom et al., 2008; Tumurkhuu et al., 2010).
The molecular basis of these disorders has been linked to mutations in components or reg-
ulators of the Ras/mitogen-activated protein kinase (MAPK) pathway, predominantly encoded
by PTPN11, BRAF, SOS1, HRAS, KRAS, MAP2K1, MAP2K2 and RAF1 genes (Ko et al., 2008;
Ezquieta et al., 2012; Search by Disease). The RAF1 gene encodes a proto-oncogene serine/
threonine-protein kinase of 648 amino acids. Structurally, the Raf-1 (also known as c-Raf) protein
has three conserved regions (CR). Mutations identified in this gene are clustered in the CR2
domain, with only a few located in CR3 (Pandit et al., 2007; Razzaque et al., 2007). The CR2 domain
is important for the regulatory phosphorylation and binding with the 14-3-3 consensus site.
Mutations located around Ser259 lead to decreased phosphorylation of the serine and dis-
sociation from the 14-3-3 binding site, thus targeting the substrate to the catalytic domain in
the CR3 domain (Kobayashi et al., 2010). Functional analysis showed that dephosphorylation
of Ser259 by RAF1 mutations at this residue leads to extracellular signal-regulated kinases
(ERK1 and ERK2) activation (Kobayashi et al., 2010).
HCM is frequently observed in patients with RASopathies and might represent the major
determinant in the outcome of these patients (Limongelli et al., 2006). Interestingly, a striking
correlation between RAF1 mutations and HCM has already been described (Razzaque et al.,
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2007; Ko et al., 2008; Wilkinson et al., 2012; Gelb et al., 2015;
Calcagni et al., 2018). It has been noted that Noonan syndrome
patients with HCM have a worse risk profile compared to patients
with idiopathic or familial HCM (Prendiville et al., 2014).
Here we report on a Tunisian patient with severe Noonan syn-
drome including neonatal HCM, leading ultimately to death. The
aim of this study was to determine the genetic defect underlying
the severe clinical phenotype of the patient.
2. Materials and methods
The parents provided their written informed consent to participate
in this study. This work was conducted according to the principles
of the Declaration of Helsinki and to the ethical guidelines of the
institutions involved (Registration number: IRB00005445,
FWA00010074). Genomic DNA was extracted from the samples
according to standard techniques.
(i) Whole exome sequencing
Whole exome sequencing (WES) was performed for the par-
ents, the affected child and her unaffected brother by the
Genomics and Bioinformatics Platform (GBiM) of the INSERM
U1251 Marseille Medical Genetics facility.
The samples were sequenced using library preparation protocols
with theNimbleGen SeqCap EZMedExome kit (Roche Sequencing
Solutions, Madison, USA). The resulting libraries were subjected to
paired-end sequencing on Illumina NextSeq 500 platform
(Illumina, San Diego, CA, USA). Raw data were aligned against
the human genome (hg19) using BWA 0.7.5. Variant calling and
annotation were processed using GATK and ANNOVAR.
(ii) Variant prioritization
Pedigree-based variant prioritization and co-segregation were
performed with the Variant Annotation and Filtering Tool
(VarAFT), version 2.12 (https://varaft.eu/). To pinpoint putatively
pathogenic and causal variants we adopted the following filtering
strategy: we first excluded variants with a minor allele frequency
(MAF) >1% in the gnomAD database (http://gnomad.broadinsti-
tute.org/). The remaining variants were filtered based on their
type and genomic localization; thus, synonymous, intronic, var-
iants in intergenic, 3´ and 5´ UTR regions were discarded. The
obtained variants list was then filtered according to the in silico
pathogenicity prediction. Thus, variants predicted as polymorph-
isms according to UMD-Predictor (http://umd-predictor.eu/),
SIFT (http://sift.jcvi.org/), PolyPhen-2 (http://genetics.bwh.har-
vard.edu/pph2/), or Mutation Taster (http://www.mutationtaster.
org/) were excluded. Subsequently, we searched for variants in
the RAS/MAPK pathway by focusing on 20 genes previously asso-
ciated with RASopathies (Table A1).
(iii) Sanger validation
The selected variant was validated using PCR-based bidirec-
tional Sanger sequencing.
3. Results
(i) Clinical presentation
The patient, a Tunisian girl, was the second child of apparently
healthy and unrelated parents. She had a healthy 4-year-old
brother. The mother and the father were respectively 33 and
39 years at conception. The family history was unremarkable.
Pregnancy was uneventful. The child was delivered by caesarian
section in the 40th week of pregnancy because of engagement fail-
ure. The Apgar scores were 9 at one minute and 10 at 5 minutes.
Her birth measurements were normal (50–90th percentiles)
(Table 1).
She was admitted 42 hours after birth in the neonatal depart-
ment because of dyspnea, cardiac murmur and dysmorphic facial
features. At 5 days, she was diagnosed with non-obstructive hyper-
trophic cardiomyopathy with a moderate pulmonary hypertension
at 46 mmHg. She was treated with propranolol (4 mg/day).
Transfontanellar and renal ultrasound examination were normal.
Serum creatinine, thyroid function tests, ammonia and lactate
levels were normal. Complete blood count revealed hypochromic
anemia treated with iron therapy. The mother’s HbA1c was normal
(5.1%). R-banded chromosome analysis on cultured peripheral
blood lymphocytes from the patient was normal 46,XX. The
chest computed tomography scan, carried out at 12 days, ruled
out coarctation of the aorta. Rhythmic Holter, carried out at 40
days, showed a normal sinus rhythm with heart rate of 133 beats
per minute and increased P wave amplitude. Echocardiography
controlled at 5months showed concentric asymmetric hypertrophy
of the ventricles and interventricular septum leading to a mild right
ventricular outflow tract obstruction (maximum gradient between
pulmonary artery and right ventricle = 16 mm) (Figure 1 &
Table 1). A patent foramen ovale and a moderate dynamic mitral
insufficiency were also noted.
Consequently, the girl was referred to a pediatric and meta-
bolic department for further investigations. Clinical evaluation
by pediatricians and geneticists found a severe failure to thrive
(Table 1). The dysmorphic facial features including large fore-
head, frontal bossing, bitemporal narrowing, shallow orbital
ridge, hypertelorism, exophthalmos, down-slanting palpebral fis-
sures, depressed root of nose and moderate bulbous tip, ante-
verted nares, low-set, posteriorly rotated ears with thickened
helix, smooth long philtrum, small mouth, thin lips, retrognathia
and a short neck with excess nuchal skin (Figure 2). Cutaneous
abnormalities were remarkable including sparse hair, eyebrows
and eyelashes, redundant and loose skin on body members,
hands and feet, and deep palmoplantar creases (Figure 2). A pec-
tus excavatum and umbilical hernia were also noted. Heart aus-
cultation indicated systolic murmur without features of heart
failure. Neurologic examination showed axial and peripheral
hypertonia with large joint stiffness. Metabolic investigations (lac-
tate cycle, plasma free and total carnitine levels, chromatographic
analysis of amino acids and organic acids) were normal. The
patient was diagnosed with Noonan syndrome or CFC, as key fea-
tures of these syndromes were present, namely the characteristic
facies, the failure to thrive, the HCM, the pectus excavatum and
the cutaneous abnormalities. Molecular testing for a germline
RASopathy was indicated.
At the age of 6 months, at blood sampling, the patient
showed some changes in facial appearance; the philtrum
became deeply grooved, the lips thicker, the nose bulbous and
the cheeks full, which were most suggestive of Noonan syndrome
(Figure 2).
On the last evaluation, at 8 months, she had a severe stunted
growth (Table 1), more evident dysmorphic face, cardiac murmur,
mild hepatomegaly, normal psychomotor development and a nor-
mal pulmonary examination. However, she died at home of a
respiratory infection a few days later.
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Table 1. Evolution of growth and echocardiographic features.
Age Neonatal (first week) 5 months 8 months
Weight Grams 3600 4300 3800
Percentile 50–75th <3rd <3rd
Height Centimeters 49.5 54 55
Percentile 50th <3rd <3rd
Head circumference Centimeters 37 40 41
Percentile 90th <3rd <3rd
IVS 9 mm 10 mm NA
PLVW 6 mm 8 mm NA
IVS, interventricular septum thickness; NA, not available; PLVW, posterior left ventricular thickness.
Fig. 1. Echocardiogram at the age of 5 months showing concentric HCM (a) and right ventricular outflow tract dilation (b).
Fig. 2. Photographs of the patient at 5 months (a, b, e, f, g) and 6 months (c, d): note the dysmorphic facial features (a, b, c, d) including large forehead, frontal
bossing, bitemporal narrowing, shallow orbital ridge, hypertelorism, exophthalmos, down-slanting palpebral fissures, depressed root of nose and bulbous tip, ante-
verted nares, low-set, posteriorly rotated ears with thickened helix (b, d), smooth long philtrum (a) becoming deeply grooved (c), small mouth, thickening of lips (c),
full cheeks (c) and retrognathia (b, d) and the cutaneous abnormalities including sparse hair, eyebrows and eyelashes (a, b, c, d), redundant and loose skin on body
members (e), hands and feet (f), and deep palmoplantar creases (g).
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(ii) Whole exome sequencing
Considering the overlapping features between Noonan and
CFC syndrome in our patient, her severe clinical profile and the
genetic heterogeneity of RASopathies, we performed exome
sequencing of the patient, her unaffected brother and both parents
to identify the disease-causing mutation. WES data from the fam-
ily were simultaneously analysed and segregated using VarAFT
software (Desvignes et al., 2018). The filtering strategy is detailed
in the ‘Materials and Methods’ section.
By focusing on 20 genes of the RAS/MAPK pathway, only one
exonic variant in exon 7 of the RAF1 genewas found. All remaining
variants were intronic. All variants in the RAS/MAPK genes iden-
tified in the affected child are listed in the Supplementary Material
(second sheet). The RAF1: c.776C > A; p.Ser259Tyr missense vari-
ant occurred de novo. The genomic coordinates of this variant in
the human assembly GRCh37/hg19 is chr3:12,645,693-12,645,693.
To review the mutation spectrum of Noonan syndrome and
specifically the RAF1 gene, the European Network on Noonan
Syndrome and related disorders was queried. The PTPN11 gene
is the most implicated gene in Noonan syndrome (61%), followed
by SOS1 and RAF1 genes (15 and 6%, respectively).
Approximately 91% of RAF1 variants are associated with
Noonan syndrome (Search by Disease). Moreover, six variant
alleles were reported at the Ser259 residue (Table 2). The
p.Ser259Tyr has only been reported once in a fatal case of
Noonan syndrome (Hakami et al., 2016).
To assess the functional impact of the p.Ser259Tyr variant,
several in silico prediction tools were used (Table 3).
Moreover, the RAF1 c.776C > A; p.Ser259Tyr is absent from
the following databases: gnomAD (http://gnomad.broadinstitute.
org), 1000 Genomes (http://www.internationalgenome.org), and
GME Variome (http://igm.ucsd.edu/gme/). Therefore, no fre-
quency data were available. The variant was also absent from
our in-house database, gathering WES data from 70 Tunisian
individuals (140 chromosomes).
This result as well as the mode of transmission were validated
by Sanger sequencing. The electropherograms shown in Figure 3
confirmed the p.Ser259Tyr mutation and the mode of
inheritance.
Overall, the heterozygous RAF1 p.Ser259Tyr variant identified
by WES confirms the diagnosis of Noonan syndrome in our
patient.
4. Discussion
We report on an 8-month-old girl affected with Noonan syn-
drome and neonatal HCM. She had a severe clinical phenotype,
resulting in a fatal outcome. The clinical presentation included
neonatal HCM, facial dysmorphism, severe failure to thrive, cuta-
neous abnormalities and pectus excavatum. These clinical and
dysmorphic facial features were suggestive of Noonan syndrome.
Nevertheless, the patient had remarkable dermatological features
including sparse hair, eyebrows and eyelashes, redundant skin
and deep palmoplantar creases. Of note, sparse hair, sparse eye-
lashes and cutaneous abnormalities can be pronounced in CFC
(Lee et al., 2011).
WES was performed and showed a de novo p.Ser259Tyr muta-
tion in exon 7 of RAF1. RAF1 or CRAF is an entry point to the
RAS/MAPK pathway. It acts as a downstream effector of RAS sig-
nalling alongside BRAF (Dhillon et al., 2002). RAF1 activation
initiates a MAPK cascade that comprises a sequential phosphoryl-
ation of the dual-specific MAPK kinases MEK1/MEK2 (encoded
by the MAP2K1 and MAP2K2 genes) followed by the extracellular
signal-regulated kinases ERK1 and ERK2 (encoded by MAPK3
and MAPK1, respectively) (Dhillon et al., 2002; Pandit et al.,
2007). The conserved region CR2 of RAF1 plays a key role in
its activation. Interestingly, the majority of RAF1 mutations are
located in the CR2 domain. Functional characterization showed
that the in vitro activity of RAF1 proteins with mutations in the
CR2 domain are higher than the activity of normal RAF1 in the
presence of growth factor (Lee et al., 2011). Activation and inacti-
vation states of RAF1 are regulated by the phosphorylation of sev-
eral serine and threonine residues. In its inactive conformation,
the N-terminal region of RAF1 interacts with the kinase domain
at the C-terminal region and leads to its inactivation. This con-
formation is stabilized by the consensus 14-3-3 recognition
sequence that binds to phosphorylated Ser259 and Ser621
(Pandit et al., 2007). It has also been demonstrated that RAF1
Table 2. Allelic heterogeneity of the p.Ser259 residue of RAF1 gene.
c.DNA Protein Classification Count Phenotype Reference
c.776C > G p.Ser259Cys Mutation 2 Noonan syndrome Unpublished
c.776_777delinsTA p.Ser259Leu Mutation 1 LEOPARD Kuburović et al., 2011
c.775T > A p.Ser259Thr Mutation 1 Noonan syndrome Lee et al., 2011
c.776C > T p.Ser259Phe Mutation 2 LEPOARD/Noonan syndrome Pandit et al., 2007
c.775T > C p.Ser259Pro Mutation 2 Noonan syndrome Unpublished
c.776C > A p.Ser259Tyr Mutation 1 Noonan syndrome Hakami et al., 2016
Table 3. Indications of pathogenicity of the p.Ser259Tyr mutation.
In silico prediction tool Prediction
CADD-score (Combined Annotation Dependent
Depletion)
26.1
LRT (Likelihood Ratio Test) Deleterious
Mutation Taster Disease causing
UMD-Predictor Pathogenic
PolyPhen-2 (Polymorphism Phenotyping v2) Damaging
Provean (Protein Variation Effect Analyzer) Damaging
SIFT (Sorting Intolerant From Tolerant) Damaging
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mutants in the CR2 domain impaired phosphorylation of Ser259,
abrogated the binding to the 14-3-3 site and lead to a partial acti-
vation of ERK (Kobayashi et al., 2010; Tumurkhuu et al., 2010).
Thus, the lack of phosphorylation of Ser259 is the primary patho-
genic mechanism in activating RAF1 mutants (Dhillon et al.,
2002; Kobayashi et al., 2010). Gain-of-function mutations in the
RAF1 gene lead to constitutive activation of the RAS/MAPK path-
way (Hopper et al., 2015).
Gain-of-function mutations in RAF1 were identified in 3–17%
of patients with Noonan syndrome and two patients with Noonan
syndrome with multiple lentigines (Pandit et al., 2007; Razzaque
et al., 2007). In a case series study reporting 212 newborns with
clinical suspicion of Noonan syndrome and related disorders,
the RAF1; p.Ser259Tyr mutation was reported in one patient
with Noonan syndrome (Hakami et al., 2016). No clinical data
of this patient were provided, except a severe edema detected by
ultrasonography (Hakami et al., 2016). Therefore, our patient is
the second case reported in the literature carrying the
p.Ser259Tyr mutation. However, allelic heterogeneity at Ser259
residue was noted (Table 2). As an illustration, the p.Ser259Thr
mutation was functionally characterized by assaying the activation
status of the downstream effectors, MEK2 and ERK2. In the pres-
ence of epidermal growth factor stimulus, a higher level of phos-
phorylated MEK1 and ERK2 was observed in cells expressing
p.Ser259Thr than in those expressing wild-type RAF1 (Lee
et al., 2011).
Our patient had neonatal non-obstructive HCM with mild
pulmonary hypertension. Previous studies noted that HCM in
Noonan syndrome arises early in life, with a median age of 5
months (Hickey et al., 2011; Wilkinson et al., 2012). HCM
might represent the major determinant in the outcome of these
patients (Limongelli et al., 2006; Wilkinson et al., 2012), particu-
larly in patients with early onset of HCM (Calcagni et al., 2018).
HCM and pulmonic stenosis are the most common cardiac
abnormalities in RAF1 mutation carriers (Kobayashi et al.,
2010). Sudden deaths in patients with RAF1 mutations has been
likely associated with heart abnormalities and their complications
(Kobayashi et al., 2010; Wilkinson et al., 2012). The molecular
pathogenesis of HCM in RASopathies results from hyperactiva-
tion of several signalling pathways (Calcagni et al., 2018).
Pandit et al. noted that Noonan syndrome patients with HCM
carried gain-of-function RAF1 mutations resulting in increased
ERK activation, whereas Noonan syndrome patients without
HCM harbour loss-of-function RAF1 mutations (Pandit et al.,
2007). These findings suggest that enhanced ERK activation
may underlie cardiomyocyte hypertrophy.
Interaction of signal transduction pathways such as the MAPK
pathway and their activators may underlie cardiac hypertrophy
(Rohini et al., 2010). The exposure of cardiomyocytes to stress
leads to the activation of small G proteins such as Ras and
Raf, which further activates MAPK signalling. Hence, the
activation of the RAS/RAF/MEK/MAPK cascade is an integral
part of the pathogenesis of HCM (Sala et al., 2012). Of note, in
vivo inhibition of MEK attenuates cardiac growth in both induced
and genetic models of hypertrophy (Armstrong, 2004; Sala et al.,
2012).
Fig. 3. Pedigree of the family. Affected proband is denoted by filled circle, unaffected members are denoted by empty symbols. Sequence electropherograms are
shown below symbols. (+) indicates the wild-type allele, the arrow indicates the position of the mutation.
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At 5 months, echocardiography of our patient revealed a con-
centric asymmetric hypertrophy of the ventricles and interventri-
cular septum. Indeed, biventricular hypertrophy has been noted
in patients with Noonan syndrome carrying RAF1 mutations
(Sana et al., 2014; Thompson et al., 2017). Moreover, HCM in
RASopathies is characterized by asymmetrical hypertrophy with
major involvement of basal interventricular septum (Calcagni
et al., 2018). Altogether, the clinical presentation described in
this study and the in silico prediction of the functional impact
of RAF1 p.Ser259Tyr mutation strengthens its claim to
pathogenicity.
In conclusion, WES allowed us to identify a de novo
p.Ser259Tyr mutation in RAF1 and to provide a definite diagnosis
of Noonan syndrome. Differential diagnosis of Noonan syndrome
and related disorders is relevant due to their different manage-
ment and prognosis as well as the resulting genetic counselling.
In the present family, as the p.Ser259Tyr mutation occurred de
novo, the risk for future pregnancies is low (<1%). Moreover,
no medical follow-up will be required for their healthy second
son. This report further supports the implication of RAF1 muta-
tions in HCM pathogenesis and highlights the correlation of
p.Ser259Tyr mutation with a severe phenotype in Noonan syn-
drome. WES can improve specialized counselling, allowing
focused and brief forms of psychological assistance in a timely
manner which can play a central role in the management of psy-
chological distress and in ensuring the relative well-being of the
family.
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